Related references
Note: Only part of the references are listed.Summary From the First Kidney Cancer Research Summit , September 12-13, 2019: A Focus on Translational Research
Toni K. Choueiri et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2021)
Beyond conventional immune-checkpoint inhibition - novel immunotherapies for renal cell carcinoma
David A. Braun et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2021)
Predictive impact of an early change in serum C-reactive protein levels in nivolumab therapy for metastatic renal cell carcinoma
Hiroki Ishihara et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2020)
Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma
T.K. Choueiri et al.
ANNALS OF ONCOLOGY (2020)
C-reactive protein at 1 month after treatment of nivolumab as a predictive marker of efficacy in advanced renal cell carcinoma
Go Noguchi et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2020)
Novel Therapeutic Approaches and the Evolution of Drug Development in Advanced Kidney Cancer
Praful Ravi et al.
CANCER JOURNAL (2020)
Avelumab monotherapy as first-line or second-line treatment in patients with metastatic renal cell carcinoma: phase Ib results from the JAVELIN Solid Tumor trial
Ulka Vaishampayan et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Prognostic Value of Baseline Serum C-Reactive Protein Level in Intermediate-Risk Group Patients With Metastatic Renal-Cell Carcinoma Treated by First-Line Vascular Endothelial Growth Factor-Targeted Therapy
Kimillaru Takamatsu et al.
CLINICAL GENITOURINARY CANCER (2018)
Higher Serum C-reactive Protein Level Represents the Immunosuppressive Tumor Microenvironment in Patients With Clear Cell Renal Cell Carcinoma
Takayuki Nakayama et al.
CLINICAL GENITOURINARY CANCER (2018)
Early response of C-reactive protein as a predictor of survival in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors
Yosuke Yasuda et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2017)
The effect of kinetics of C-reactive protein in the prediction of overall survival in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitor
Jun Teishima et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2017)
Predictive value of C-reactive protein in patients treated with sunitinib for metastatic clear cell renal cell carcinoma
Martin Pilskog et al.
BMC UROLOGY (2017)
Overall survival of first-line axitinib in metastatic renal cell carcinoma: Japanese subgroup analysis from phase II study
Mototsugu Oya et al.
CANCER SCIENCE (2017)
Prognostic effect of serum C-reactive protein kinetics on advanced renal cell carcinoma treated with sunitinib
Tetsuo Fujita et al.
MOLECULAR AND CLINICAL ONCOLOGY (2017)
The impact of change in serum C-reactive protein level on the prediction of effects of molecular targeted therapy in patients with metastatic renal cell carcinoma
Jun Teishima et al.
BJU INTERNATIONAL (2016)
Key predictive factors for efficacy of axitinib in first-line metastatic renal cell carcinoma: subgroup analysis in Japanese patients from a randomized, double-blind phase II study
Yoshihiko Tomita et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2016)
Checkpoint inhibitors and other novel immunotherapies for advanced renal cell carcinoma
Maria I. Carlo et al.
NATURE REVIEWS UROLOGY (2016)
Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells
Benjamin Boyerinas et al.
CANCER IMMUNOLOGY RESEARCH (2015)
Prognostic impact of baseline serum C-reactive protein in patients with metastatic renal cell carcinoma (RCC) treated with sunitinib
Benoit Beuselinck et al.
BJU INTERNATIONAL (2014)
Overall survival and final efficacy and safety results from a Japanese phase II study of axitinib in cytokine-refractory metastatic renal cell carcinoma
Masatoshi Eto et al.
CANCER SCIENCE (2014)
Prognostic impact of pretreatment C-reactive protein for patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors
Yosuke Yasuda et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2013)
Efficacy and Safety of Axitinib Versus Sorafenib in Metastatic Renal Cell Carcinoma: Subgroup Analysis of Japanese Patients from the Global Randomized Phase 3 AXIS Trial
Takeshi Ueda et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2013)
Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial
Thomas E. Hutson et al.
LANCET ONCOLOGY (2013)
Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial
Brian I. Rini et al.
LANCET ONCOLOGY (2013)
Prognostic Factors of Patients With Metastatic Renal Cell Carcinoma With Removed Metastases: A Multicenter Study of 556 Patients
Sei Naito et al.
UROLOGY (2013)
Third generation tyrosine kinase inhibitors and their development in advanced renal cell carcinoma
Ronald M. Bukowski
FRONTIERS IN ONCOLOGY (2012)
Key predictive factors of axitinib (AG-013736)-induced proteinuria and efficacy: A phase II study in Japanese patients with cytokine-refractory metastatic renal cell Carcinoma
Yoshihiko Tomita et al.
EUROPEAN JOURNAL OF CANCER (2011)
Evaluation of baseline serum C-reactive protein (CRP) and benefit from tremelimumab compared to chemotherapy in first-line melanoma
M. A. Marshall et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Evaluation of an inflammation-based prognostic score in patients with metastatic renal cancer
Sara Ramsey et al.
CANCER (2007)
The systemic inflammatory response, performance status and survival in patients undergoing alpha-interferon treatment for advanced renal cancer
E Bromwich et al.
BRITISH JOURNAL OF CANCER (2004)
Share Paper
